TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7923540
Drug: Drug prescriptions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug prescriptions for non-diabetic patients
Study: 2800576
Drug: Butorphanol 2
Normalized name: butorphanol 2 mg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butorphanol 2 mg plus diazepam 10 mg
Study: 337758
Drug: Amipaque 290
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amipaque 290 mg I/ml
Study: 337758
Drug: Urografin 60%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urografin 60% (292 mg I/ml)
Study: 27335145
Drug: Topical rose
Normalized name: Rose Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical rose oil (in the carrier of almond oil)
Study: 26054452
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual and hypnosis (TAU+HYP)
Study: 23241726
Drug: 0.6 µg·kg·min
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 µg·kg·min remifentanil
Study: 23241726
Drug: 0.9 µg·kg·min
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9 µg·kg·min remifentanil
Study: 23241726
Drug: 0.3 µg·kg·min
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 µg·kg·min remifentanil
Study: 21880278
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral contraceptive pills (OC)
Study: 16636217
Drug: Etanercept 50
Normalized name: etanercept 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept 50 mg subcutaneously once a week for 4 weeks
Study: 15257811
Drug: 17 alpha-hydroxyprogesterone
Normalized name: 17 alpha-hydroxyprogesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17 alpha-hydroxyprogesterone caproate (17-HPC) administered intramuscularly (341 mg every 3 days)
Study: 15257811
Drug: Intra-vaginal progesterone
Normalized name: progesterone Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-vaginal progesterone (90 mg daily)
Study: 11169254
Drug: HLA-G*01011 allele
Approvals — FDA: no, EMA: no, PMDA: no
Description: HLA-G*01011 allele
Study: 11169254
Drug: HLA-G*01012 allele
Approvals — FDA: no, EMA: no, PMDA: no
Description: HLA-G*01012 allele
Study: 11169254
Drug: HLA-G*01013 allele
Approvals — FDA: no, EMA: no, PMDA: no
Description: HLA-G*01013 allele
Study: 11169254
Drug: HLA-G*01041 allele
Approvals — FDA: no, EMA: no, PMDA: no
Description: HLA-G*01041 allele
Study: 9484876
Drug: grepafloxacin, 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: grepafloxacin, 600 mg od
Study: 9484876
Drug: amoxycillin, 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: amoxycillin, 500 mg tds
Study: 23257680
Drug: Nebulized beclomethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized beclomethasone dipropionate (nBDP) 800 µg, administered twice daily for 4 weeks
Study: 17684134
Drug: Combination botanical
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination botanical supplement (Curcuma longa, Cynara scolymus, Rosmarinus officinalis, Schisandra chinensis, Silybum marinum, and Taraxacum officinalis; n = 15)
Study: 17684134
Drug: Dietary changes
Normalized name: guaifenesin / hydrocodone bitartrate Oral Solution [Canges XP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary changes (3 servings/d crucifers or dark leafy greens, 30 g/d fiber, 1‐2 liters/d water, and limiting caffeine and alcohol consumption to 1 serving each/wk; n = 10)
Study: 27707640
Drug: Burn Cool
Approvals — FDA: no, EMA: no, PMDA: no
Description: Burn Cool Spray®
Study: 3284421
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg adrenaline
Study: 3284421
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg adrenaline
Study: 3284421
Drug: Vasoconstrictors (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vasoconstrictors (0.15 mg clonidine or 0.4 mg adrenaline)
Study: 27541270
Drug: Immediate ibuprofen
Normalized name: ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Immediate ibuprofen (IIBU)
Study: 27541270
Drug: Delayed ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Delayed ibuprofen (DIBU)
Study: 27541270
Drug: No ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: No ibuprofen (NIBU)
Study: 27541270
Drug: Paracetamol (IPARA)
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paracetamol (IPARA)
Study: 27541270
Drug: Delayed paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed paracetamol (DPARA)
Study: 27541270
Drug: No paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: No paracetamol (NPARA)
Study: 23275387
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg prednisolone daily for 2 years (P-group)
Study: 19028705
Drug: Oral nicotinamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nicotinamide (1500 or 500 mg daily for 1 week)
Study: 19028705
Drug: Placebo (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (administered for 1 week)
Study: 9923984
Drug: Homeopathic preparation
Normalized name: Urtica urens homeopathic preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homeopathic preparation 'Tinnitus' (D60 potency)
Study: 7828257
Drug: Flumazenil (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil (0.1 mg.ml‐1)
Study: 31406237
Drug: Desloratadine treatment
Normalized name: Desloratadine
DrugBank: Desloratadine (DB00967)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desloratadine treatment
Study: 24242902
Drug: EMD 525797
Normalized name: Emdisterone
DrugBank: Drostanolone propionate (DB14655)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMD 525797 (DI17E6) 35, 100, 250, 500, 1000, or 1500 mg
Study: 22042368
Drug: Adjuvant aromatase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant aromatase inhibitor therapy
Study: 17693918
Drug: Placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule of insulin
Study: 10223935
Drug: Penciclovir (PCV)
Normalized name: Penciclovir
DrugBank: Penciclovir (DB00299)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penciclovir (PCV) 5 mg/kg every 12 hours (q12h)
Study: 10223935
Drug: Penciclovir (PCV)
Normalized name: Penciclovir
DrugBank: Penciclovir (DB00299)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penciclovir (PCV) 5 mg/kg every 8 hours (q8h)
Study: 10223935
Drug: Acyclovir (ACV)
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acyclovir (ACV) 5 mg/kg every 8 hours (q8h)
Study: 10150324
Drug: Ampicillin/sulbactam (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin/sulbactam (1 g + 0.5 g)
Study: 2142172
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (triethanolamine and aqueous cream)
Study: 368364
Drug: Cephalosporin therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephalosporin therapy
Study: 31113338
Drug: Shorter time
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shorter time to treatment
Study: 25721698
Drug: 100 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 μg vitamin D3 daily
Study: 25721698
Drug: 50 μg
Normalized name: penicillin G 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 μg vitamin D3 daily
Study: 20807322
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg on-demand vardenafil ODT
Study: 19491798
Drug: Sinupret in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sinupret in age-adjusted doses
Study: 17261211
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of Ondansetron 150 microg kg‐1 intravenously, second dose after 6 h (Group 3)
Study: 7933819
Drug: Pulse oral
Normalized name: dulse extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulse oral calcitriol (2 micrograms thrice weekly, increased to 4 micrograms as tolerated)
Study: 7933819
Drug: Intravenous calcitriol
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous calcitriol (2 micrograms thrice weekly, increased to 4 micrograms as tolerated)
Study: 7933819
Drug: Both pulse
Normalized name: dulse extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both pulse oral and intravenous calcitriol
Study: 2952091
Drug: Regular cigarette
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular cigarette (nicotine content: 1.1 mg)
Study: 2952091
Drug: Light cigarette
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light cigarette (nicotine content: 0.6 mg)
Study: 29807477
Drug: belimumab 200
Normalized name: belimumab 200 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: belimumab 200 mg SC
Study: 10427455
Drug: Intercostal blocks
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intercostal blocks (ICB) with 5 ml 0.5% bupivacaine at the end of surgery and 6 h later
Study: 10427455
Drug: Interpleural analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interpleural analgesia (IPA) with 20 ml 0.25% bupivacaine applied every 4 h using a catheter
Study: 29852877
Drug: Scaling and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scaling and Root Planing (SRP) followed by subgingival application of curcumin gel
Study: 24999785
Drug: Routine Fe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine Fe (n 2184; 60 mg ferrous sulfate plus 400 μg folic acid daily throughout pregnancy)
Study: 24999785
Drug: Selective Fe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective Fe (n 2142; screening and treatment for anaemia and daily intake of 1 mg folic acid)
Study: 18473021
Drug: Oral‐B Exceed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral‐B Exceed
Study: 15368824
Drug: Falls prevention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Falls prevention service intervention (falls risk assessment and evidence-based prescription to GP)
Study: 8256898
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg ciprofloxacin daily for 7 days
Study: 8256898
Drug: 300 ng
Normalized name: NG
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 ng isoniazid daily for 7 days
Study: 19001206
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation 1200 mg/d
Study: 19001206
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation 600 mg/d
Study: 1650526
Drug: Hyperfractionated radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyperfractionated radiation therapy (HFX) at 69.6 Gy
Study: 31308262
Drug: ropivacaine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: ropivacaine with clonidine 75 µg
Study: 31308262
Drug: ropivacaine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: ropivacaine with dexamethasone 8 mg
Study: 31308262
Drug: ropivacaine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: ropivacaine with buprenorphine 300 µg
Study: 26720443
Drug: ONO-9054 30.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONO-9054 30.0 μg/mL
Study: 26720443
Drug: ONO-9054 (0.3,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONO-9054 (0.3, 1.0, 3.0, 10.0, 20.0, or 30.0 μg/mL)
Study: 11791958
Drug: Artemisinin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemisinin (500 mg for adults, 10 mg/kg for children) for 5 days followed by 2 days of placebo (A5)
Study: 11791958
Drug: Artemisinin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemisinin (500 mg for adults, 10 mg/kg for children) for 7 days (A7)
Study: 9888619
Drug: Metergoline (serotonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metergoline (serotonin antagonist)
Study: 2547216
Drug: Mopidamol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mopidamol (2 x mg i.v. daily perioperatively, 3 x 500 mg orally postoperatively)
Study: 2102668
Drug: Once-daily regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily regimen
Study: 2102668
Drug: Three-time daily
Normalized name: bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Three-time daily regimen
Study: 27699880
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of UVB nb and UVA (320‐400 nm) phototherapy
Study: 21332272
Drug: Polymyxin B
Normalized name: Polymyxin B
DrugBank: Polymyxin B (DB00781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Polymyxin B sulfate, neomycin sulfate and gramicidin (PS) ear drops, thrice daily for 10 ± 2 days
Study: 21332272
Drug: Glycerol ear
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycerol ear drops, thrice daily for 10 ± 2 days
Study: 17286197
Drug: Internet administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet administered CHQ-CF questionnaire
Study: 17286197
Drug: Paper administered
Normalized name: paper birch pollen extract
DrugBank: Betula papyrifera pollen (DB10831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paper administered CHQ-CF questionnaire
Study: 17286197
Drug: Both internet
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both internet and paper administration
Study: 14749753
Drug: Fruit juices
Normalized name: Morinda citrifolia fruit juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fruit juices (1 l daily for 16 weeks)
Study: 14749753
Drug: Fruit-vegetable-concentrate (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fruit-vegetable-concentrate (30 ml daily for 16 weeks)
Study: 9794841
Drug: Daclizumab (humanized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daclizumab (humanized monoclonal antibodies against the IL-2 receptor) added to standard cyclosporin-based immunosuppression
Study: 2908433
Drug: Epanolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epanolol (100 mg twice daily for 4 weeks)
Study: 27669373
Drug: 3% sodium
Normalized name: Dextrose 5% and 0.3% Sodium Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% sodium bicarbonate saline solution for oral care
Study: 11866422
Drug: Small volume
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small volume resuscitation fluids (SVR) - a combination of hypertonic crystalloid with a colloid; specific dosage and duration not mentioned.
Study: 11866422
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline solution (HSD); specific dosage and duration not mentioned.
Study: 30297322
Drug: 7-day-dose metronidazole
Normalized name: metronidazole 7.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day-dose metronidazole (500 mg twice daily for 7 days)
Study: 22830646
Drug: Lunchtime walking
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lunchtime walking intervention in an urban environment, twice a week for 8 weeks
Study: 22830646
Drug: Lunchtime walking
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lunchtime walking intervention in a natural environment, twice a week for 8 weeks
Study: 18533183
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg mCPP with ritanserin pre-treatment
Study: 18533183
Drug: mCPP administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: mCPP administration
Study: 15674303
Drug: 0.25 g
Normalized name: AMICAR 0.25 GM/mL Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 g WA
Study: 15674303
Drug: 0.5 g
Normalized name: Gelatin Capsules, 10.5 gr
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g WA
Study: 15674303
Drug: 1.0 g
Normalized name: IODINE 11.0 g in 1 L TOPICAL SOLUTION [T.D.]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 g WA
Study: 15674303
Drug: 0.5 g
Normalized name: Gelatin Capsules, 10.5 gr
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g WA (long-term administration)
Study: 15674303
Drug: 0 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g WA (control for long-term administration)
Study: 12083587
Drug: IV parecoxib
Normalized name: parecoxib
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: IV parecoxib sodium 40 mg
Study: 12083587
Drug: morphine 4
Normalized name: morphine 4 mg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: morphine 4 mg
Study: 348229
Drug: Cephaloridine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephaloridine (3 doses of 1 g each: 1 g IV at surgery start, 1 g IM at 6 hours, 1 g IM at 12 hours)
Study: 348229
Drug: Cephaloridine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephaloridine (3 doses of 1 g each)
Study: 28335798
Drug: Anakinra 100
Normalized name: ANAKINRA 100MG INJ,SYRINGE,1ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anakinra 100 mg
Study: 26768233
Drug: Lifestyle intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lifestyle intervention (dietary counselling twice by telephone and access to twice‐weekly exercise groups)
Study: 25741842
Drug: 500 ml
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 ml HES 130/0.4
Study: 25741842
Drug: 1500 ml
Normalized name: Bag/Pump Set 1500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 ml 9‰ saline solution
Study: 16091706
Drug: F‐milk (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: F‐milk (daily approx. 0.2 l with the level 2.5 ppm)
Study: 12585183
Drug: Mifepristone and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone and Chinese herbal medicine (CHM)
Study: 12585183
Drug: Methotrexate and
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate and Chinese herbal medicine (CHM)
Study: 10941859
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin (BT) 1.2 ml injected endoscopically
Study: 10941859
Drug: Saline 1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline 1.2 ml injected endoscopically (Control)
Study: 8749123
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose ethanol (0.45 g/kg LBW)
Study: 8749123
Drug: Medium dose
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium dose ethanol (0.80 g/kg LBW)
Study: 8749123
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose ethanol (1.05 g/kg LBW)
Study: 4061105
Drug: Diltiazem 90
Normalized name: diltiazem 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 90 mg four times daily
Study: 4061105
Drug: Propranolol 60
Normalized name: propranolol 60 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 60 mg four times daily
Study: 4061105
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of diltiazem and propranolol (90 mg and 60 mg respectively, both four times daily)
Study: 30505414
Drug: Surgical-site injections
Normalized name: SOLO SITE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical-site injections (SIs) with a mixture of epinephrine hydrochloride, morphine sulfate, ropivacaine HCL, and normal saline.
Study: 30505414
Drug: Surgical-site injections
Normalized name: SOLO SITE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical-site injections (SIs)
Study: 30505414
Drug: No surgical-site
Approvals — FDA: no, EMA: no, PMDA: no
Description: No surgical-site injections (no-SI)
Study: 30505414
Drug: Surgical-site injections
Normalized name: SOLO SITE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical-site injections (SIs) and no-SI
Study: 26693818
Drug: Pharmacotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy with spironolactone addition
Study: 24359050
Drug: Intramuscular dexketoprofen
Normalized name: dexketoprofen
DrugBank: Dexketoprofen (DB09214)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular dexketoprofen trometamol with paracervical block
Study: 24359050
Drug: Intramuscular dexketoprofen
Normalized name: dexketoprofen
DrugBank: Dexketoprofen (DB09214)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular dexketoprofen trometamol without paracervical block
Study: 15208157
Drug: Ethanol (0.45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (0.45 g/kg b.w.) with placebo
Study: 15208157
Drug: Ethanol (0.45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (0.45 g/kg b.w.) with propranolol (40 mg at 08:00 and 20 mg at 12:00)
Study: 9602954
Drug: Terbinafine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbinafine (250 mg daily for 3 days)
Study: 15025403
Drug: TNX-901 (450
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNX-901 (450 mg)
Study: 15025403
Drug: TNX-901 (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNX-901 (150 mg)
Study: 15025403
Drug: TNX-901 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNX-901 (300 mg)
Study: 11242179
Drug: Cotrimoxazole (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cotrimoxazole (80 mg of trimethoprim and 400 mg of sulphamethoxazole daily)
Study: 12196422
Drug: Troglitazone 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troglitazone 600 mg
Study: 9745421
Drug: Troglitazone 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troglitazone 600 mg (diet-only subset)
Study: 9745421
Drug: Troglitazone 200
Normalized name: troglitazone 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troglitazone 200 mg (sulfonylurea subset)
Study: 9745421
Drug: Troglitazone 400
Normalized name: troglitazone 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troglitazone 400 mg (sulfonylurea subset)
Study: 9745421
Drug: Troglitazone 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troglitazone 600 mg (sulfonylurea subset)
Study: 9745421
Drug: Troglitazone 400
Normalized name: troglitazone 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troglitazone 400 mg and 600 mg
Study: 2109465
Drug: Flumazenil (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil (0.5 mg i.v.)
Study: 31669449
Drug: Hybrid designs
Normalized name: Amaranthus hybridus pollen
DrugBank: Amaranthus hybridus pollen (DB15503)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hybrid designs in vaccine development
Study: 28385433
Drug: Simplified edentulous
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simplified edentulous treatment (SET)
Study: 25609193
Drug: Trelagliptin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trelagliptin (100 mg once per week)
Study: 25609193
Drug: Alogliptin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alogliptin (25 mg once per day)